Amycretin significantly improves weight loss in patients with overweight or obese body weight
1. The majority of treatment-related adverse events were mild-to-moderate gastrointestinal events with no reported deaths.
2. Amycretin resulted in significant weight loss across most doses compared to placebo.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Amycretin is a novel therapy that activates GLP-1 and amylin receptors, two hormones involved in regulating appetite and metabolism. Until now, there has been scarce evidence regarding the role of amycretin in promoting weight loss for patients with overweight and obese body-mass indices (BMI). This randomized controlled trial aimed to evaluate the efficacy and safety of amycretin, administered once weekly over up to 36 weeks, in adults with overweight or obesity. The primary outcome of this study was the number of treatment-emergent adverse events, while the key secondary outcome was the relative change in body weight from baseline. According to study results, amycretin significantly increased weight loss compared to placebo and was associated with mild-moderate gastrointestinal adverse events. Although this study was well done, it was limited by a high dropout rate, which limits the validity of the study results.
Click to read the study in The Lancet
Relevant Reading: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
In-depth [randomized controlled trial]: Between Sept 15, 2023, and Apr 14, 2024, 198 individuals were assessed for eligibility at a single research center in Texas, USA. Included were patients aged 18–55 years with overweight or obesity (BMI 27.0–39.9 kg/m²) who were randomly allocated to receive either amycretin or placebo. Altogether, 125 patients (101 in amycretin and 24 in placebo) were included in the final analysis. Most treatment-related adverse events were mild to moderate, being primarily gastrointestinal in nature. The secondary outcome of relative change in body weight was significantly greater with amycretin compared to placebo (-24.4% vs. -1.1% in 60 mg, -22.0% vs 1.9% in 20 mg, and -16.2% vs. 2.3% in 5 mg, p<0.0001 for all). Findings from this study suggest that amycretin is a promising treatment for weight loss with a tolerability profile similar to other GLP-1 and amylin receptor agonists.
Image: PD
©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
